Century Therapeutics (IPSC) Asset Writedowns and Impairment (2023 - 2025)

Century Therapeutics (IPSC) has reported Asset Writedowns and Impairment for 3 consecutive years, with $6.8 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $6.8 million; the TTM figure through Sep 2025 stood at $11.1 million (down 8.69% YoY), while the FY2025 annual figure was $6.8 million, up 56.3% from the prior year.
• Asset Writedowns and Impairment advanced to $6.8 million in Q3 2025 per IPSC's latest filing, from $4.3 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $12.1 million in Q4 2023 and bottomed at $4.2 million in Q2 2023.
• Historically, Asset Writedowns and Impairment has averaged $6.9 million across 3 years, with a median of $5.5 million in 2024.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 64.37% in 2024 and fell as far as 64.37% in 2024.
• Century Therapeutics' Asset Writedowns and Impairment stood at $12.1 million in 2023, then plunged by 64.37% to $4.3 million in 2024, then surged by 56.3% to $6.8 million in 2025.
• Business Quant data shows IPSC's Asset Writedowns and Impairment at $6.8 million in Q3 2025, $4.3 million in Q4 2024, and $12.1 million in Q4 2023.